Cheng, Yu
Liu, Shuai
Chen, Duo
Yang, Yiman
Liang, Qiongyue
Huo, Ya
Zhou, Ziyi
Zhang, Nan
Wang, Zhuo
Liu, Lishun
Song, Yun
Liu, Xiangyi
Duan, Yong
Liang, Xiuwen
Hou, Bingjie
Wang, Binyan
Tang, Genfu
Qin, Xianhui
Yan, Fangrong
Funding for this research was provided by:
the National Key Research and Development Program of China (2016YFE0205400, 2018ZX09739010, 2018ZX09301034003)
the Science and Technology Program of Guangdong, China (2020B121202010)
the Science and Technology Planning Project of Guangzhou (201707020010)
the Science, Technology and Innovation Committee of Shenzhen, China (GJHS20170314114526143, JSGG20180703155802047)
the Economic, Trade and Information Commission of Shenzhen Municipality, China (20170505161556110, 20170505160926390, 201705051617070)
the National Natural Science Foundation of China (81730019, 81973133, 81960074, 81500233)
the Research Fund Program of Guangdong Provincial Key Laboratory of Renal Failure Research, Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2018GZR0201003)
Jiangxi Outstanding Person Foundation (20192BCBL23024)
the Major projects of the Science and Technology Department, Jiangxi, China (20171BAB205008)
Article History
Received: 8 November 2021
Accepted: 8 May 2022
First Online: 13 May 2022
Declarations
:
: The parent study (the China Stroke Primary Prevention Trial, CSPPT) was approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University, Hefei, China (federal-wide assurance number: FWA00001263). All participants provided written, informed consent.
: All the co-authors are approval for publication.
: The co-authors declare no competing interests.